Subscribe to Pro or Enterprise plans to unlock this feature.
Become a smarter investor today.
Become a smarter investor today.
This statistic highlights Emergent BioSolutions Revenue by Product, split between ACAM2000, Anthrax vaccines, BioThrax, NARCAN Nasal Spray and Other products, reported on a quarterly basis from Q1 2016 onwards.
|Revenue by Product||Q3 2020||Q2 2021||Q3 2021||Contribution in Q3 2021|
|NARCAN Nasal Spray||$88.80||$106.20||$133.30||49.27%|
(All figures in millions, except percentages)
Emergent BioSolutions specializes in therapies that treat and protect against public health threats. It offers vaccines and medicines.
In the year 2020, Emergent BioSolutions generated total revenue of $648.90 million from product sales, which decreased in the next year 2021 to $589.60 million, showing a year-on-year decline of 9.13%.
In Q3 2020, it reported total revenue of $202.20 million, which increased in Q3 2021 to $270.50, showing a quarter-on-quarter increase of 33.37%. In Q2 2021, the company earned total revenue of $181.20, which further showed growth of 49.28% in Q3 2021.
Emergent BioSolutions earnings from products are further bifurcated in the following:
NARCAN is a medicine that snappily reverses an opioid overdose. It serves as an opioid antagonist. It blocks the possession of opiates to relieve hazardous symptoms caused by a high level of opiates in the blood. It is injected into a muscle that is given in the outer thigh. NARCAN is mostly used as a saving drug for individuals who suffer from an opioid overdose which is made available in 41 states; This drug is easily available in retail medical shops and is also covered by health insurance policies. However, it doesn’t help to reverse overdoses caused by alcohol or cocaine.
In the year 2020, Emergent BioSolutions product NARCAN Nasal Spray earned revenue of $233.80 million, which increased in the next year 2021 to $313.70 million, indicating year-on-year growth of 34.17%. NARCAN Nasal Spray revenue increased in Q3 2021, from $88.80 million to $133.30 million (Q3 2020), indicating quarter-on-quarter growth of 51.27%. In Q2 2020, this product earned revenue of $106.20 million, which showed growth in Q3 2021, by earning revenue of $133.30 million and contributing 49.27% to the total revenue of the company.
ACAM2000 (Smallpox Vaccine) is a smallpox vaccine that is manufactured to provide immunization against smallpox disease; it is specially produced for those who have a high risk of smallpox infection. This vaccine is also licensed in Singapore and Australia and currently, it is being traded in the United States and Internationally.
In the year 2020, Emergent BioSolutions product, ACAM2000, reported revenue of $71.00 million, which increased in the next year 2021 to $80.70 million, showing year-on-year growth of 13.66%. In Q3 2020, it earned revenue of $1.00 million, which further increased to $80.70 million, in Q3 2021, indicating quarter-on-quarter growth of 7,970% and contributing 29.63% to the total revenue of the company. However, in Q2 2021, it faced a loss and not earned revenue.
Other products include medicines named AstraZeneca, RSDL (Reactive Skin Decontamination Lotion).
In the year 2020, Emergent BioSolutions’ other product earned revenue of $86.00 million, which decreased in the next year 2021, to $73.10 million, indicating a year-on-year decline of 17.64%. In Q3 2020, it generated revenue of $38.50 million, which further increased in Q3 2021, indicating year-on-year growth of 6.12%. However, in Q2 2021, its revenue declined and it made revenue of $23.50, which increased in Q3 2021 by 74.04% and contributed 15.12% to the total revenue of the company.
Anthrax vaccine has a three-dose series and is given over 18 months. This vaccine is also given to the employees who come in contact with infectious animals; also it was given to the soldiers.
In the year 2020, Emergent BioSolutions product Anthrax vaccines earned revenue of $258.10 million, which increased in the next year 2021, to $122.10 million, indicating year-on-year growth of 111.3%. In Q3 2020, it generated revenue of $73.90 million, which showed a drastic decline of $15.60 million in Q3 2021, indicating quarter-on-quarter growth of 78.80%. Similarly, due to government intervention and high competition, this segment showed a decline in its revenue in Q2 2021 by generating revenue of $51.50 million, which decreased to $15.50 and contributed 5.76% to the total revenue of the company.
Emergent BioSolutions is a global US state-owned and multinational corporation. It was founded on 5 September 1998 and incorporated in 2003. The company has its headquarters in Gaithersburg, Maryland. The business transforms into EBS, develops and supplies vaccines and therapeutic antibodies for transmission.
The society creates pharmaceutical products for infectious diseases such as typhoid and cholera. It offers medicines and vaccinations for travel-related and viruses.
Did you like Emergent BioSolutions Revenue by Product statistic?
Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.
You can get started here.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.